Literature DB >> 18507665

An antibody to the aggregated synthetic prion protein peptide (PrP106-126) selectively recognizes disease-associated prion protein (PrP) from human brain specimens.

Michael Jones1, Darren Wight, Victoria McLoughlin, Katherine Norrby, James W Ironside, John G Connolly, Christine F Farquhar, Ian R MacGregor, Mark W Head.   

Abstract

Human prion diseases are characterized by the conversion of the normal host cellular prion protein (PrP(C)) into an abnormal misfolded form [disease-associated prion protein (PrP(Sc))]. Antibodies that are capable of distinguishing between PrP(C) and PrP(Sc) may prove to be useful, not only for the diagnosis of these diseases, but also for a better understanding of the molecular mechanisms involved in disease pathogenesis. In an attempt to produce such antibodies, we immunized mice with an aggregated peptide spanning amino acid residues 106 to 126 of human PrP (PrP106-126). We were able to isolate and single cell clone a hybridoma cell line (P1:1) which secreted an IgM isotype antibody [monoclonal antibody (mAb P1:1)] that recognized the aggregated, but not the monomeric form of the immunogen. When used in immunoprecipitation assays, the antibody did not recognize normal PrP(C) from non-prion disease brain specimens, but did selectively immunoprecipitate full-length PrP(Sc) from cases of variant and sporadic Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. These results suggest that P1:1 recognizes an epitope formed during the structural rearrangement or aggregation of the PrP that is common to the major PrP(Sc) types found in the most common forms of human prion disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18507665     DOI: 10.1111/j.1750-3639.2008.00181.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  6 in total

Review 1.  Understanding amyloid fibril formation using protein fragments: structural investigations via vibrational spectroscopy and solid-state NMR.

Authors:  Benjamin Martial; Thierry Lefèvre; Michèle Auger
Journal:  Biophys Rev       Date:  2018-05-31

2.  PrPSc-Specific Antibody Reveals C-Terminal Conformational Differences between Prion Strains.

Authors:  Eri Saijo; Andrew G Hughson; Gregory J Raymond; Akio Suzuki; Motohiro Horiuchi; Byron Caughey
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

3.  Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment.

Authors:  Nives Skrlj; Tanja Vranac; Mara Popović; Vladka Curin Šerbec; Marko Dolinar
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

4.  PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers.

Authors:  Mourad Tayebi; Daryl Rhys Jones; William Alexander Taylor; Benjamin Frederick Stileman; Charlotte Chapman; Deming Zhao; Monique David
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

Review 5.  Prion protein-specific antibodies-development, modes of action and therapeutics application.

Authors:  Tihana Lenac Rovis; Giuseppe Legname
Journal:  Viruses       Date:  2014-10-01       Impact factor: 5.048

6.  The N-terminal sequence of prion protein consists an epitope specific to the abnormal isoform of prion protein (PrP(Sc)).

Authors:  Kentaro Masujin; Yuko Kaku-Ushiki; Ritsuko Miwa; Hiroyuki Okada; Yoshihisa Shimizu; Kazuo Kasai; Yuichi Matsuura; Takashi Yokoyama
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.